The U.S. Food and Drug Administration (FDA) has approved Edurant (rilpivirine), a new non-nucleoside reverse transcriptase inhibitor (NNRTI)—the class of HIV meds that also includes Sustiva (efavirenz). Edurant is approved for people who haven't taken HIV drugs before. Like all HIV meds, it's taken with other drugs to make a complete combo. (Search “Edurant” at for more information.) And watch for a new tablet that will combine Edurant and Truvada (tenofovir/emtricitabine) for an all-in-one HIV regimen. It's expected later this year.